Published in PLoS Pathog on August 07, 2014
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathog (2015) 1.04
HIV: A stamp on the envelope. Nature (2014) 0.88
Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnology (2016) 0.88
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells. PLoS Pathog (2015) 0.86
High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Rep (2016) 0.84
Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology (2015) 0.83
Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev (2017) 0.83
A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA. PLoS One (2015) 0.82
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv Biol (2014) 0.81
Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat Commun (2016) 0.78
Design of virus-based nanomaterials for medicine, biotechnology, and energy. Chem Soc Rev (2016) 0.77
Dense array of spikes on HIV-1 virion particles. J Virol (2017) 0.75
The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J Control Release (2016) 0.75
Enhanced potency of bivalent small molecule gp41 inhibitors. Bioorg Med Chem (2016) 0.75
Arms Race between Enveloped Viruses and the Host ERAD Machinery. Viruses (2016) 0.75
Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. Malar J (2016) 0.75
Covalent linkage of HIV-1 trimers to synthetic liposomes elicits improved B cell and antibody responses. J Virol (2017) 0.75
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol (2006) 3.04
Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell (2014) 2.36
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
Few and far between: how HIV may be evading antibody avidity. PLoS Pathog (2010) 1.94
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med (2013) 1.68
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
The influence of virus structure on antibody responses and virus serotype formation. Immunol Today (1996) 1.50
HPV - immune response to infection and vaccination. Infect Agent Cancer (2010) 1.48
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol (2002) 1.48
Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol (2004) 1.44
Molecular underpinning of B-cell anergy. Immunol Rev (2010) 1.20
Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol (2008) 1.13
Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine (1999) 1.07
Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS (2014) 0.95
Active immunotherapy for chronic diseases. Vaccine (2013) 0.94